Peiwen Ma

1.2k total citations
36 papers, 843 citations indexed

About

Peiwen Ma is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peiwen Ma has authored 36 papers receiving a total of 843 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peiwen Ma's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (5 papers). Peiwen Ma is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (5 papers). Peiwen Ma collaborates with scholars based in China, United States and Ireland. Peiwen Ma's co-authors include Shuhang Wang, Ning Li, Huilei Miao, Yan Zha, Ning Jiang, Shujun Xing, Kun Chen, Qiyu Tang, Yuan Fang and Zicheng Yu and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Brain.

In The Last Decade

Peiwen Ma

31 papers receiving 827 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peiwen Ma China 13 380 346 249 135 90 36 843
Daniel Wilkinson United States 13 290 0.8× 377 1.1× 168 0.7× 88 0.7× 26 0.3× 21 699
Mirco Friedrich Germany 14 180 0.5× 164 0.5× 282 1.1× 134 1.0× 68 0.8× 37 791
Jessica Chacon United States 13 552 1.5× 446 1.3× 201 0.8× 63 0.5× 45 0.5× 36 754
David C. Binder United States 17 759 2.0× 681 2.0× 298 1.2× 124 0.9× 94 1.0× 37 1.4k
Ying‐Hsu Chang Taiwan 14 275 0.7× 77 0.2× 232 0.9× 153 1.1× 37 0.4× 56 808
Robert Doherty United States 12 148 0.4× 205 0.6× 293 1.2× 209 1.5× 21 0.2× 38 782
Stephen K. Lau United States 11 338 0.9× 194 0.6× 358 1.4× 87 0.6× 35 0.4× 28 807
Jianghua Yan China 19 153 0.4× 103 0.3× 450 1.8× 258 1.9× 42 0.5× 53 866
Jun Pang China 23 286 0.8× 120 0.3× 566 2.3× 226 1.7× 36 0.4× 91 1.3k
Phillip M. Galbo United States 17 325 0.9× 271 0.8× 392 1.6× 63 0.5× 15 0.2× 29 960

Countries citing papers authored by Peiwen Ma

Since Specialization
Citations

This map shows the geographic impact of Peiwen Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peiwen Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peiwen Ma more than expected).

Fields of papers citing papers by Peiwen Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peiwen Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peiwen Ma. The network helps show where Peiwen Ma may publish in the future.

Co-authorship network of co-authors of Peiwen Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Peiwen Ma. A scholar is included among the top collaborators of Peiwen Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peiwen Ma. Peiwen Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Xingyu, Yuan Fang, Peiwen Ma, et al.. (2025). Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy. Med. 6(10). 100849–100849. 1 indexed citations
2.
Cai, Yuanting, Zhao Guo, Peiwen Ma, et al.. (2025). Harnessing the power of TCR-T cell therapy: A new era in cancer immunotherapy. Cancer Letters. 613. 217507–217507. 1 indexed citations
3.
4.
Guo, Zhao, Yuning Wang, Shujun Xing, et al.. (2024). Exosome-based anticancer vaccines: From Bench to bedside. Cancer Letters. 595. 216989–216989. 22 indexed citations
5.
Guo, Zhao, Yuning Wang, Jiawei Zhou, et al.. (2024). Pan-cancer analysis of polo-like kinase family genes reveals polo-like kinase 1 as a novel oncogene in kidney renal papillary cell carcinoma. Heliyon. 10(8). e29373–e29373. 2 indexed citations
6.
Guo, Zhao, Hong Fang, Yale Jiang, et al.. (2024). Nanoparticle drug delivery system for the treatment of brain tumors: Breaching the blood–brain barrier. Acta Pharmaceutica Sinica B. 14(6). 2786–2789. 3 indexed citations
7.
Ma, Peiwen, Yale Jiang, Zhao Guo, et al.. (2024). Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review. European Journal of Cancer. 209. 114224–114224. 6 indexed citations
8.
Jiang, Yale, Ning Jiang, Shujun Xing, et al.. (2024). Bridging the gap: unlocking the potential of emerging drug therapies for brain metastasis. Brain. 148(3). 702–722. 4 indexed citations
9.
Zhou, Jiawei, Peiwen Ma, Yale Jiang, et al.. (2024). First report: PLATFORM study for precision treatment of rare tumors in China. Cancer Letters. 597. 217021–217021. 1 indexed citations
10.
Jiang, Ning, Yue Yu, Dawei Wu, et al.. (2023). HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events. Journal of Cancer Research and Clinical Oncology. 149(2). 737–747. 19 indexed citations
11.
Chen, Kun, Shuhang Wang, Dan Qi, et al.. (2022). Clinical Investigations of CAR-T Cell Therapy for Solid Tumors. Frontiers in Immunology. 13. 896685–896685. 20 indexed citations
12.
Jiang, Ning, Yue Yu, Min Zhang, et al.. (2022). Association between germ-line HLA and immune-related adverse events. Frontiers in Immunology. 13. 952099–952099. 19 indexed citations
13.
Yang, Yuqi, Shuhang Wang, Peiwen Ma, et al.. (2022). Drug conjugate-based anticancer therapy - Current status and perspectives. Cancer Letters. 552. 215969–215969. 67 indexed citations
14.
Wang, Shuhang, Qin Li, Peiwen Ma, et al.. (2022). KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients. Frontiers in Molecular Biosciences. 9. 831382–831382. 10 indexed citations
15.
Wang, Shuhang, Peiwen Ma, Yan Zha, et al.. (2022). CAR-macrophage: An extensive immune enhancer to fight cancer. EBioMedicine. 76. 103873–103873. 96 indexed citations
16.
Pan, Xuewei, et al.. (2022). A Game-Theoretic Approach of Optimized Operation of AC/DC Hybrid Microgrid Clusters. Energies. 15(15). 5537–5537. 10 indexed citations
17.
Wang, Shuhang, Keman Cheng, Kun Chen, et al.. (2022). Nanoparticle-based medicines in clinical cancer therapy. Nano Today. 45. 101512–101512. 122 indexed citations
18.
Wang, Shuhang, Lu Li, Peiwen Ma, et al.. (2022). Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development. Vaccines. 10(8). 1168–1168. 4 indexed citations
19.
Wang, Shuhang, Lei Qi, Peiwen Ma, et al.. (2021). An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020. Drug Discovery Today. 27(5). 1236–1250. 29 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Wilkinson Breakdown of academic impact, for papers by Mirco Friedrich Breakdown of academic impact, for papers by Jessica Chacon Breakdown of academic impact, for papers by David C. Binder Breakdown of academic impact, for papers by Ying‐Hsu Chang Breakdown of academic impact, for papers by Robert Doherty Breakdown of academic impact, for papers by Stephen K. Lau Breakdown of academic impact, for papers by Jianghua Yan Breakdown of academic impact, for papers by Jun Pang Breakdown of academic impact, for papers by Phillip M. Galbo
Rankless by CCL
2026